Keyword: Almirall

Almirall is the latest drugmaker to pony up millions of dollars to wrap up allegations it paid doctors for to jack up prescription numbers.

Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land.

Almirall's focus shift to skin now includes new branding. “Feel the Science” is the specialty pharma’s relaunched identity and tagline.

AstraZeneca has some positive new COPD data in hand—and it’s data that could help the company snag a new approval.

Sanofi’s loss is Almirall’s gain. In its second diabetes exec shift since last May, EVP Peter Guenter jumped to the top job at derm-focused Almirall.

Acne's no fun in high school, and one dermatology drugmaker is hoping a virtual-reality trip to teenage land will remind healthcare providers just how that felt.

Troubled Valeant may have a buyer to help it pull off some of the asset sales it’s been touting as it looks to cut down its debt pile.

Almirall's dermatology focus will get a boost with a new skin disease awareness campaign. The Barcelona-based pharma’s digital work called the “Shared Skin Initiative” features 5 Almirall employees made up with various skin conditions to show the emotional impact of dermatological diseases.